M. Jakóbisiak
Immunology · 2008–2014
A researcher in the Science corpus: 2 papers; trusts 3 researchers and is trusted by 0 researchers here, as inferred from the citation graph.
Subfields
- Immunology — 25 citations into it
- Oncology — 14 citations into it
Whom M. Jakóbisiak trusts
Their strongest outbound trust, strongest first, inferred from their citations.
- N. Restifo (in Immunology)
- T. Waldmann (in Immunology)
- S. Rosenberg (in Immunology)
Papers from M. Jakóbisiak's perspective
Ordered by how strongly the researchers M. Jakóbisiak trusts endorse each paper. Same corpus, a different order for every researcher.
- Reversible Defects in Natural Killer and Memory Cd8 T Cell Lineages in Interleukin 15–Deficient Mice (Journal of Experimental Medicine)
- IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8+ T Cells (Proceedings of the National Academy of Sciences of the United States of America)
- Adoptive cell transfer: a clinical path to effective cancer immunotherapy (Nature Reviews. Cancer)
- The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design (Nature reviews. Immunology)
- Synergy of IL-21 and IL-15 in regulating CD8+ T cell expansion and function (Journal of Experimental Medicine)
- Cancer Regression in Patients After Transfer of Genetically Engineered Lymphocytes (Science)
- Cancer immunotherapy: moving beyond current vaccines (Nature Medicine)
- Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells. (Proceedings of the National Academy of Sciences of the United States of America)
- Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells. (Journal of Clinical Investigation)
- Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia (New England Journal of Medicine)
Their papers
- Interleukin 12: still a promising candidate for tumor immunotherapy? (2014) — 441 citations
- Statins Impair Antitumor Effects of Rituximab by Inducing Conformational Changes of CD20 (2008) — 1,849 citations